Andrew Cutler, MD

Cutler told HCPLive it was surprising that a new survey on subcutaneous TEV- ‘749 revealed 50% and 45.5% of nurses and physicians, respectively, preferred intramuscular injections.

HCPLive spoke with Cutler on recent phase 3 SOLARIS data and what distinguishes TEV-‘749 from other long-acting injectables.

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.

Dr Andrew Cutler and Dr Greg Mattingly comment about emerging treatments to treat anhedonia and highlight lifestyle modifications that support the wellbeing of patients with Major Depressive Disorder.

Dr Andrew Cutler and Dr Greg Mattingly review current understanding of anhedonia. They discuss how clinicians can better evaluate it by effectively and candidly communicating with patients about anhedonia.

The expert psychiatrists discuss when to evaluate treatment efficacy and the impact of patients’ quality of life and function in such evaluations.

Dr Andrew Cutler and Dr Greg Mattingly talk about patient profiles they consider for treatment with dextromethorphan-bupropion.

The expert psychiatrists share their clinical experience with dextromethorphan-bupropion.

Dr Greg Mattingly reviews the results of GEMINI and ASCEND trials, which led to approval of dextromethorphan-bupropion.

Dr Greg Mattingly explains the mechanism of action of dextromethorphan-bupropion, a new agent to treat Major Depressive Disorder.

Dr Andrew Cutler and Dr Greg Mattingly discuss newer mechanisms of action to treat patients with Major Depressive Disorder, in particular those with glutamatergic agents.

Dr Greg Mattingly shares his view on major challenges in the management of Major Depressive Disorder and limitations of medications currently used.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the need to improve awareness around depressive disorders and break the stigma of mental health treatment.

Experts in psychiatry review emerging mechanisms of action in the treatment landscape of MDD.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, share their approach to treatment-resistant depression.

Drs Andrew J. Cutler, Gregory Mattingly, and Sagar V. Parikh discuss the treatment of MDD in female patients who are pregnant or plan to become pregnant.

Experts in psychiatry review factors to consider when deciding to switch or augment treatment in major depressive disorder [MDD].

Drs Andrew J Cutler, Gregory Mattingly, and Sagar V Parikh provide advice to clinicians on monitoring treatment in major depressive disorder.

Experts in psychiatry provide insight into treating episodic vs chronic major depressive disorder and factors they consider when approaching treatment selection.

Andrew J Cutler, MD; Gregory Mattingly, MD; and Sagar V Parikh, MD, FRCPC, discuss clinical data on zuranolone from the WATERFALL, CORAL, and SHORELINE studies for the treatment of major depressive disorder.

Use of Zuranolone for Treatment of MDD

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, review newly approved additions to the major depressive disorder treatment landscape, including esketamine, brexanolone, AXS-05 (dextromethorphan/bupropion).

Experts in psychiatry discuss unmet needs in the treatment of major depressive disorder and how new agents are aiming to fulfill these needs.

Andrew J. Cutler, MD; Gregory Mattingly, MD; and Sagar V. Parikh, MD, FRCPC, comment on the limitations and challenges of traditional treatments for MDD, such as length of treatment and adverse events.

Sagar V. Parikh, MD, FRCPC, reviews factors that lead to the use of antidepressants in the treatment of MDD.

Gregory Mattingly, MD, provides an overview of currently available treatment options for MDD.